Document Detail


Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.
MedLine Citation:
PMID:  19189932     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tumefactive demyelinating lesions are a known but uncommon complication of multiple sclerosis, a disease rarely reported in children. This is the case of a 16-year-old African American patient with multiple sclerosis, who developed 2 tumefactive demyelinating lesions. Review of the literature and our own experience helped formulate an algorithm for therapeutic options during an acute attack.
Authors:
Jahannaz Dastgir; Francis J DiMario
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-02-02
Journal Detail:
Title:  Journal of child neurology     Volume:  24     ISSN:  1708-8283     ISO Abbreviation:  J. Child Neurol.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-02     Completed Date:  2009-08-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8606714     Medline TA:  J Child Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  431-7     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Division of Child Neurology, Connecticut Children's Medical Center, Hartford, Connecticut 06106, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease / therapy
Adolescent
Brain / pathology*,  physiopathology
Cyclophosphamide / therapeutic use
Demyelinating Diseases / pathology*,  physiopathology,  therapy
Facial Nerve Diseases / etiology
Frontal Lobe / pathology,  physiopathology
Hemiplegia / etiology
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use
Interferon-beta / therapeutic use
Magnetic Resonance Imaging
Male
Methylprednisolone / therapeutic use
Multiple Sclerosis / pathology*,  physiopathology,  therapy
Nerve Fibers, Myelinated / pathology
Ocular Motility Disorders / etiology
Paresis / etiology
Pons / pathology,  physiopathology
Recurrence
Treatment Outcome
Vertigo / etiology
Chemical
Reg. No./Substance:
0/Immunoglobulins, Intravenous; 0/Immunosuppressive Agents; 145258-61-3/interferon beta 1a; 50-18-0/Cyclophosphamide; 77238-31-4/Interferon-beta; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Methyl-CpG-binding Protein 2 (MECP2) Gene Mutations in an Italian Sample of Patients with Pervasive ...
Next Document:  Kindergarten Children's Failure to Qualify for First Grade Could Result From Sleep Disturbances.